Wambaugh John F, Wetmore Barbara A, Pearce Robert, Strope Cory, Goldsmith Rocky, Sluka James P, Sedykh Alexander, Tropsha Alex, Bosgra Sieto, Shah Imran, Judson Richard, Thomas Russell S, Setzer R Woodrow
*National Center for Computational Toxicology and
The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709-2137;
Toxicol Sci. 2015 Sep;147(1):55-67. doi: 10.1093/toxsci/kfv118. Epub 2015 Jun 16.
Toxicokinetic (TK) models link administered doses to plasma, blood, and tissue concentrations. High-throughput TK (HTTK) performs in vitro to in vivo extrapolation to predict TK from rapid in vitro measurements and chemical structure-based properties. A significant toxicological application of HTTK has been "reverse dosimetry," in which bioactive concentrations from in vitro screening studies are converted into in vivo doses (mg/kg BW/day). These doses are predicted to produce steady-state plasma concentrations that are equivalent to in vitro bioactive concentrations. In this study, we evaluate the impact of the approximations and assumptions necessary for reverse dosimetry and develop methods to determine whether HTTK tools are appropriate or may lead to false conclusions for a particular chemical. Based on literature in vivo data for 87 chemicals, we identified specific properties (eg, in vitro HTTK data, physico-chemical descriptors, and predicted transporter affinities) that correlate with poor HTTK predictive ability. For 271 chemicals we developed a generic HT physiologically based TK (HTPBTK) model that predicts non-steady-state chemical concentration time-courses for a variety of exposure scenarios. We used this HTPBTK model to find that assumptions previously used for reverse dosimetry are usually appropriate, except most notably for highly bioaccumulative compounds. For the thousands of man-made chemicals in the environment that currently have no TK data, we propose a 4-element framework for chemical TK triage that can group chemicals into 7 different categories associated with varying levels of confidence in HTTK predictions. For 349 chemicals with literature HTTK data, we differentiated those chemicals for which HTTK approaches are likely to be sufficient, from those that may require additional data.
毒代动力学(TK)模型将给药剂量与血浆、血液及组织浓度联系起来。高通量毒代动力学(HTTK)通过体外到体内的外推,根据快速的体外测量和基于化学结构的性质来预测毒代动力学。HTTK的一个重要毒理学应用是“反向剂量测定”,即将体外筛选研究中的生物活性浓度转化为体内剂量(毫克/千克体重/天)。预计这些剂量会产生与体外生物活性浓度相当的稳态血浆浓度。在本研究中,我们评估了反向剂量测定所需的近似值和假设的影响,并开发了方法来确定HTTK工具是否适用于特定化学品,或者是否可能导致错误结论。基于87种化学品的体内文献数据,我们确定了与HTTK预测能力差相关的特定性质(例如,体外HTTK数据、物理化学描述符和预测的转运体亲和力)。对于271种化学品,我们开发了一种通用的基于生理学的高通量毒代动力学(HTPBTK)模型,该模型可预测各种暴露场景下非稳态化学物质浓度随时间的变化过程。我们使用这个HTPBTK模型发现,以前用于反向剂量测定的假设通常是合适的,但对于生物累积性很强的化合物尤其不适用。对于目前没有毒代动力学数据的环境中的数千种人造化学品,我们提出了一个化学毒物代动力学分类的四要素框架,该框架可将化学品分为7个不同类别,与对HTTK预测的不同置信水平相关。对于349种有文献报道的HTTK数据的化学品,我们区分了哪些化学品的HTTK方法可能足够,哪些可能需要额外的数据。